Ocumension Therapeutics has announced that its product, OT-703 (ILUVIEN®), has been approved for a real-world study in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China. OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant designed for the treatment of diabetic macular edema $(DME.AU)$. The implant provides a continuous microdose of corticosteroid fluocinolone acetonide in the eye for up to 36 months. It is the only FDA-approved corticosteroid intraocular implant with a three-year sustained-release period, and it has recently received regulatory approval in Hong Kong. Ocumension holds exclusive rights for its development and commercialization in Greater China, South Korea, and parts of Southeast Asia, following a licensing agreement with Alimera Sciences, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。